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Left ventricular assist devices have provided successful supportive therapy 
for patients awaiting cardiac transplantation for extended periods of time. 
Although thromboembolic events have complicated support with these 
devices, the HeartMate left ventricular assist device developed by Thermo 
Cardiosystems, Inc., Woburn, Massachusetts, was specifically designed 
with a textured blood-contacting surface to minimize this risk. Clinical 
experience with this device has been encouraging, inasmuch as minimal 
thromboembolic omplications have occurred despite the absence of anti- 
coagulation. The coagulation and fibrinolytic pathways in these individuals 
were investigated to better understand the hematologic status of patients 
treated with the Thermo Cardiosystems device. Despite apparently normal 
prothrombin and activated partial thromboplastin times, as well as platelet 
counts, evidence of significant thrombin generation and fibrinolysis was 
present. To eliminate underlying cardiac failure as the responsible factor 
for these abnormalities, we made similar measurements in patients with 
end-stage heart failure who were not supported by an assist device or 
anticoagulation. These measurements revealed no evidence of thrombin 
generation or fibrinolysis. These data demonstrate that patients supported 
with a left ventricular assist device, while successfully sustained without 
systemic anticoagulation, nevertheless have evidence of activation of coag- 
ulation. These phenomena ppear to be related to the presence of the device 
rather than to the underlying cardiac abnormalities. Although procoagu- 
lant and fibrinolytic pathways are apparently balanced in these patients, 
these data underscore the potential for the development of bleeding or 
thrombosis in clinically relevant settings. (J Thorac Cardiovasc Surg 1996; 
112:1090-7) 
C ardiac transplantation has become the accepted standard of care for patients with end-stage heart 
failure. The ever-widening gap between the number 
of potential cardiac transplant recipients and the 
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number of available donor organs, 1-3 however, has 
necessitated the development of intermediate or 
"bridging" devices designed to sustain the patient 
awaiting an appropriate donor heart. The success of 
these pumps has prompted a movement oward 
their use as a permanent form of cardiac replace- 
ment. 4-s One of the critical factors limiting the use 
of left ventricular assist devices (LVADs) in the past 
has been a reported rate of thromboembolic com- 
plications of 30% or greater, as well as a significant 
perioperative coagulopathy. 9-12 
Compared with the early LVADs, whose surfaces 
were mainly smooth, the HeartMate LVAD de- 
veloped by Thermo Cardiosystems, Inc., Woburn, 
Massachusetts, was designed with specific features 
intended to minimize the potential for thromboem- 
bolic complications. 13-17 Specifically, this LVAD, 
containing a textured surface, was designed to facil- 
itate the formation of a tightly adherent "pseudo- 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 4 
Spanier et al. 1091 
Table I. Demographic profile of patients having LVADs 
Age Length of L VAD Type of 
(YO Sex Diagnosis treatment (days) L VAD pump* 
1 52 F Idiopathic CM 335 Pneumatic 
2 65 M Ischemic CM 46 Pneumatic 
3 51 M Ischemic CM 139 Pneumatic 
4 19 M Idiopathic CM 35 Electric 
5 61 M Ischemic CM 101 Electric 
6 17 M Idiopathic CM 65 Electric 
7 61 M Ischemic CM 100 Electric 
8 58 M Ischemic CM 70 Electric 
9 58 M Ischemic CM 68 Pneumatic 
10 48 M Ischemic CM 221 Electric 
11 68 M Ischemic CM 56 Pneumatic 
12 39 F Subacute MI 49 Pneumatic 
13 56 M Ischemic CM 9 Pneumatic 
14 51 F Subacute M1 7 Pneumatic 
15 65 M Ischemic CM 33 Electric 
16 59 F Ischemic CM 35 Pneumatic 
17 65 M Ischemic CM 33 Pneumatic 
18 52 M Idiopathic CM 25 Pneumatic 
19 51 M Ischemic CM 11 Pneumatic 
20 30 M Idiopathic CM 5 Pneumatic 
CM, Cardiomyopathy; MI, myocardial infarction. 
*HeartMate LVAD; Thermo Cardiosystems, Inc., Woburn, Massachusetts. 
neointima" on the blood-contacting surfaces, a 
strategy aimed at reducing the risk of thromboem- 
bolism by eliminating direct contact between the 
device and circulating blood. 17 A thromboembol ic 
rate of less than 2% has been associated with the use 
of this device in patients receiving no or minimal 
forms of anticoagulation. ~8
To better understand the hematologic profile that 
underlies this low thromboembol ic  risk and to more 
fully understand the long-term physiologic implica- 
tions of its use, we analyzed measurements of 
thrombin generation and fibrinolysis in patients 
supported by the HeartMate LVAD.  
Patients and methods 
Patients. Twenty patients in clinically stable condition 
with implanted Thermo Cardiosystcms HeartMate 
LVADs and 12 other patients in clinically stable condition 
with New York Heart Association class IV heart failure 
were entered into this study during the period extending 
from June 1995 through November 1995. The study was 
conducted in accordance with the rules and regulations of 
the Institutional Review Board of Columbia University 
College of Physicians and Surgeons. Among the patients 
supported with an LVAD, 14 had pneumatically driven 
LVADs and the other six had electrically driven LVADs. 
The mean age of the patients with an LVAD was 51.7 
years (range 17 to 65 years) and the mean duration of 
LVAD treatment was 83 days (range 5 to 335 days). No 
patients in the LVAD group were receiving heparin, 
warfarin sodium, or other systemic anticoagulant therapy. 
Five patients were receiving aspirin (325 mg by mouth 
every day) (Table I). The 12 patients with class IV 
end-stage heart failure were selected for inclusion in this 
study because they were not receiving systemic anticoag- 
ulation. Their mean age was 54 years (range 33 to 65 
years). All patients in this group were receiving aspirin 
(325 mg by mouth every day). 
Values for a normal control population were ob- 
tained from the clinical laboratories at Columbia Pres- 
byterian Medical Center for prothrombin time, acti- 
vated partial thromboplastin time, levels of platelets 
and fibrinogen, fibrinogen (fibrin) degradation products 
(FDPs), and D-dimers. These values were obtained by 
examining blood samples of 30 normal volunteers. 
Normal values for thrombin-antithrombin complex 
(TAT), prothrombin activation peptide (FI+z), and 
soluble thrombomodulin were provided by the manu- 
facturers from which the enzyme-linked immunosor- 
bent assay (ELISA) kits were obtained. These values 
were derived by analysis of plasma samples from 120 
clinically stable volunteers. Levels of F 1 +2 are a specific 
reflection of the effects of factor Xa on prothrombin 
and thus are a marker of thrombin generation and 
activation of coagulation. ~9-2° 
Materials. After peripheral blood had been obtained in 
accordance with the aforementioned protocols, complete 
blood count, prothrombin time, activated partial throm- 
boplastin time, fibrinogen levels, and FDPs were obtained 
from the clinical laboratories of Columbia University 
College of Physicians and Surgeons according to standard 
methods. ELISAs for TAT and F~+ 2 were obtained from 
Behring Diagnostics, Inc, (Westwood, Mass.), and ELISA 
kits for D-dimers and soluble thrombomodulin were 
obtained from American Diagnostica (Greenwich, 
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Fig. 1. Assessment of routine coagulation parameters in patients with LVADs and patients with end-stage 
heart failure (ESHF). Plasma was obtained by peripheral venipuncture from the patients with LVADs or 
end-stage heart failure as described in the text. Parameter (normal control) values were obtained from the 
clinical coagulation laboratory of Columbia Presbyterian Medical Center. Mean values _+ standard 
deviation for prothrombin time, activated partial thromboplastin time, and levels of platelets and 
fibrinogen are depicted within the bar graphs. No significant differences were noted except hat patients 
with end-stage heart failure had higher levels of fibrinogen than patients with LVADs and normal control 
subjects (p < 0.02). 
Conn.). All ELISAs were performed according to the 
manufacturers' instructions. 
Statistical analysis. Data were analyzed with SAS Sys- 
tem software (SAS Institute, Inc., Cary, N.C.). The 
Kruskal-Wallis test (X a approximation 21) and the non- 
parametric analog of the analysis of variance were used to 
test the differences in means across the three groups 
(LVAD, end-stage heart failure, and normal). If the 
Kruskal-Wallis test showed significant differences, then a 
nonparametric multiple comparisons test was applied to 
determine among which groups statistically significant 
differences existed. 22' 23 Differences were considered sig- 
nificant if the probability value (p value) for comparison 
was less than 0.05. 
Results 
As previously described, plasma was obtained 
from patients at random times during LVAD ther- 
apy which corresponded to our study period. The 
mean length of LVAD implantation at the time of 
blood sampling was 87 days (range 5 to 335 days). 
The patients were all in clinically stable condition 
when they were tested. Blood sampling was per- 
formed in the morning in all cases, but no samples 
were obtained with the patient fasting. As stated 
previously, no patients were receiving oral or intra- 
venous anticoagulant therapy. Five of the patients 
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Fig. 2. Assessment of thrombin generation i patients with LVADs and in patients with end-stage heart 
failure (ESHF). Peripheral blood was obtained as described in the text and plasma was assayed as described 
for FI+ 2 and TAT. Mean values _+ standard eviation are shown within the bargraphs. Levels of FI+ 2 and 
TAT were significantly higher in patients with LVADs than in patients with end-stage heart failure and 
than the normal control values (p < 0.002 and p < 0.0001, respectively). 
were receiving aspirin at a dosage of 325 mg one 
time a day. Normal population control values were 
obtained from our clinical laboratories or from the 
manufacturers of the respective assay kits used in 
these experiments. Plasma was also obtained from 
patients with class IV heart failure to eliminate the 
presence of heart failure as a cause of the observed 
coagulation abnormalities. These samples were sim- 
ilarly taken in the morning, but not with the patient 
fasting. All of these patients were receiving aspirin 
(325 mg orally every day), but none was receiving 
anticoagulant therapy. 
Our initial studies revealed that there were no 
significant differences between patients supported 
by an LVAD and the normal population with re- 
spect to platelet count, prothrombin and partial 
thromboplastin times, and levels of plasma fibrino- 
gen. Comparison with patients in end-stage heart 
failure also failed to reveal any significant differ- 
ences in any of these studies (Fig. 1). 
To evaluate more subtle indices indicative of 
activation of the procoagulant pathway, we mea- 
sured levels of TAT and FI+ 2. Evaluation of these 
markers of thrombin generation revealed that pa- 
tients supported with an LVAD had statistically 
significantly higher levels of TAT (p < 0.0001) and 
FI+ 2 (p < 0.0001) than the control population (Fig. 
2). Similarly, these markers of thrombin generation 
were significantly higher in patients with an LVAD 
than in patients with end-stage heart failure (p < 
0.002). There were no discernible differences be- 
tween patients with pneumatically driven or electri- 
cally powered LVADs with respect o markers of 
thrombin generation, or were differences detected 
in LVAD patients receiving aspirin compared with 
those receiving no antiplatelet therapy (data not 
shown). 
To investigate whether enhanced fibrinolysis ac- 
companied activation of the procoagulant pathway, 
we evaluated patients for the presence of D-dimers 
and FDPs. Compared with the normal control pop- 
ulation and patients with end-stage heart failure, 
patients with an LVAD had significantly higher 
levels of plasma D-dimers and FDPs (p < 0.0001 
and p < 0.0001, respectively) (Fig. 3). Levels of 
D-dimer and FDP in patients with an LVAD were 
similarly elevated irrespective of the type of LVAD 
or treatment with aspirin (data not shown). 
We examined levels of soluble thrombomodulin 
as an additional marker of endothelial disturbance 
potentially caused by the effects of microemboli 
generated in the coagulopathy associated with 
LVAD therapy. Soluble thrombomodulin, most 
likely made and released by the endothelium, 24 was 
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Fig. 3. Assessment of activation of fibrinolysis in patients with LVADs and patients with end-stage heart 
failure (ESHF). Peripheral blood was obtained as described inthe text and plasma was assayed as described 
for levels of D-dimers and FDPs. Mean values _+ standard eviation are shown within the bargraphs. Levels 
of D-dimers were significantly higher in patients with LVADs than in patients with end-stage heart failure 
and than the normal control values (p < 0.002 and p < 0.002, respectively). Levels of FDPs were 
significantly higher in patients with LVADs than in patients with end-stage heart failure and than the 
normal control values (p < 0.0001 and p < 0.0001, respectively). 
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Fig. 4. Elevation of soluble thrombomodulin in patients 
with LVADs: a possible marker of endothelial perturba- 
tion. Peripheral blood was obtained as described in the 
text and plasma was assayed as described for levels of 
soluble thrombomodulin. Mean values of soluble throm- 
bomodulin 2 standard eviation are shown within the bar 
graphs. Levels of soluble thrombomodulin were signifi- 
cantly higher in patients with LVADs than the normal 
control values (p < 0.002). There was no significant 
difference in levels of soluble thrombomodulin in patients 
with LVADs and patients with end-stage heart failure 
sustained without anticoagulation. 
at a higher concentration i the plasma of patients 
with an LVAD than in normal subjects (p < 0.002) 
(Fig. 4). Increased plasma soluble thrombomodulin 
is likely to result from endothelial perturbation 
caused by a number of factors including sustained 
activation of coagulation and fibrinolytic pathways, 
altered blood flow, or other vascular changes conse- 
quent to the presence of the LVAD. 
Discussion 
Our data indicate that patients with Thermo 
Cardiosystems HeartMate LVADs have significant 
activation of coagulation with secondary fibrinolysis, 
despite both apparent clinical stability and "normal" 
screening values of routine hemostatic parameters 
such as platelet count, prothrombin time, and acti- 
vated partial thromboplastin time. Soluble thrombo- 
modulin, derived from an integral membrane pro- 
tein constitutively expressed by endothelium, 2g is 
likely to be shed or proteolyzed as a result of 
endothelial perturbation, perhaps related to the 
presence of the LVAD or to microemboli associated 
with activation of coagulation (Fig. 5). From a 
clinical standpoint, the extent of activation of the 
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Fig. 5. Soluble thrombomodulin. We postulate that sol- 
uble thrombomodulin, likely derived from the integral 
membrane protein constitutively expressed by the endo- 
thelium, is shed and/or proteolyzed as a result of endo- 
thelial perturbation caused by the presence of the LVAD. 
Such inciting causes as the presence of microemboli in a 
procoagulant milieu, altered flow characteristics with cel- 
lular activation, and/or other vascular factors associated 
with the LVAD itself are likely contributory factors. 
thrombin-generating and fibrinolytic pathways ap- 
pears balanced in these patients; our earlier studies 
demonstrated low (2%) thromboembolic complica- 
tion rates associated with the use of this LVAD. 18 
Furthermore, clinical experience does not demon- 
strate a bleeding or thrombotic diathesis in the 
nonstressed or nonsurgical setting. 4-8' ,4-i8 
The causes underlying these hemostatic abnor- 
malities are of considerable interest. Such LVAD- 
specific auses as the textured polyurethane surface, 
the titanium housing, and the Dacron inflow/outflow 
lines need to be considered. Other causes, such as 
altered flow characteristics and the presence of 
preexisting clots in the diseased ventricles, must also 
be investigated. Our data do not suggest that these 
findings are a direct result of the surgical implanta- 
tion procedure of the LVAD, inasmuch as hemo- 
static findings remain abnormal at least up to day 
335 of LVAD therapy (see Figs. 1 to 4). In this 
context, Livingston and colleagues 25 have shown 
that in the perioperative period, patients with an 
LVAD consistently have significantly higher mark- 
ers of thrombin generation (TAT and F1+2) and 
fibrinolysis (D-dimers and FDPs) than do patients 
who have had coronary bypass grafting. 25 Our pilot 
studies, in which we prospectively examined patients 
having LVADs, do not demonstrate hat these peri- 
operative findings are sustained, because the overt 
indices of thrombin generation and fibrinolysis are 
acute and procedure-related. In fact, pilot studies in 
two patients examined to date have revealed that 
markers of thrombin generation/fibrinolysis aresig- 
nificantly elevated uring the operation, return to 
Prothrombotic stimulus ° LVAD surface 
• Dacron inflow/outflow tracts 
~+'- * altered flow 
prothrombin i ~ thrombin 
fibrinogen ~ fibrin 
\ . . .~. 
:T~I?~ fibrin clot [~  fibrinolysis 
23 
plasminogen ~ plasmin ~ ' '  
Fig. 6. Coagulation cascade/fibrinolysis. As demon- 
strated by our studies, evidence exists for significant 
thrombin generation (as reflected by increased levels of 
TAT and Fl+2) and fibrinolysis (increased levels of D- 
dimers and FDPs) in patients with LVADs compared with 
values for the normal control population and values for 
patients with end-stage heart failure not supported by 
LVAD or anticoagulant therapy. The mechanism(s) un- 
derlying the generation ofa procoagulant state are not yet 
clear. For example, it is not known whether activation of 
the intrinsic and/or extrinsic pathways of coagulation 
underlie these findings. Closed arrows are indicative of the 
procoagulant pathway resulting in the formation of a 
fibrin clot. Open arrows follow the fibrinolytic pathway. 
Dotted arrows and open font signify the markers of these 
pathways reported in this study. 
near-normal values by days 5 to 7 after the opera- 
tion, and then rise in a time-dependent manner, 
peaking at approximately day 35 of LVAD therapy, 
an effect that is subsequently sustained (data not 
shown). 
Indeed, these data suggest that a specific charac- 
teristic of the LVAD itself is responsible, at least in 
part, for these observations. In this context, we and 
others have demonstrated considerable cellular en- 
trapment by this device in studies of explanted 
LVaDs. 26-30 Flow cyt0metry studies have demon- 
strated that the majority of these ceils are myeloid/ 
monocytic in origin. In addition, a smaller percent- 
age of the cells are pluripotential hematopoietic 
cells, which can be induced to differentiate in culture 
to mature hematopoietic cells) ° Menconi and col- 
leagues 29 found that the surface of explanted 
LVADs contained adherent mononuclear cells, 
platelets, and myofibroblasts intermingled with ar- 
eas of compact fibrinous material, as well as areas of 
collagenous tissue. Similarly, Salih and colleagues26 
found the surface of the explanted LVAD polyure- 
thane membrane to consist of fibrinous and cellular 
layers. The layer atop the membrane was composed 
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of a compact fibrin coating, as well as numerous 
mononuclear cells and spindle-shaped cells. An 
intermediate middle layer consisted of cells resem- 
bling fibroblasts and fewer mononuclear cells than 
were observed in the inner layer. The outermost 
layer, at the biomaterial/tissue interface, contained a
foreign body reaction with numerous multinucle- 
ated giant cells. Sections of tissue islands removed 
from the titanium surface revealed organized fi- 
brous and collagenous tissue with few cellular areas, 
except for occasional mononuclear cells. Whereas 
Salih and colleagues found no evidence of endothe- 
lial cells on the surface of the LVAD, other studies 
have disputed this. Specifically, Frazier and col- 
leagues 27 found evidence for the presence of endo- 
thelial cells on the pseudointimal lining of the 
textured LVAD surface. Using antibodies to yon 
Willebrand factor, they demonstrated positive im- 
munoreactivity in certain cells on the lining, sugges- 
tive of the presence of endothelial cells. (Of course, 
platelet material may also be responsible for this 
positive immunostaining for yon Willebrand factor.) 
The significance of defining the presence of endo- 
thelial cells in this setting cannot be overstated, 
because their presence may suggest the potential for 
restoration of normal control of the vascular proco- 
agulant and anticoagulant pathways. 
Consistent with the hypothesis that the LVAD 
surface itself contributes to the multiple biologic 
phenomena observed in the course of its use, studies 
have revealed that this lining is metabolically active. 
Menconi and associates 29 showed by ribonucleic 
acid hybridization analysis that the colonizing cells 
actively expressed genes encoding proteins for cell 
proliferation markers, cell adhesion molecules, cy- 
toskeletal structures, and extracellular matrix com- 
ponents. 
Taken together, these data suggest hat the cells 
lining the LVAD surface are not biologically inert. 
In this context, we postulate that the mononuclear 
cells, platelets, and pluripotential stem cells initially 
trapped by the polyurethane surface, titanium hous- 
ing, or Dacron grafts 25-3° may become activated, 
thus leading to the generation of a local proinflam- 
matory/procoagulant state. We further postulate 
that this mechanism is responsible, at least in part, 
for triggering and subsequently sustaining activation 
of the coagulation and fibrinolytic ascades (Fig. 6). 
In fact, our recent pilot studies have demonstrated 
that peripheral blood-derived mononuclear cells 
adhere almost immediately to representative s c- 
tions of the LVAD polyurethane surface and that, 
within days, these mononuclear cells appear to 
differentiate into mononuclear phagocyte-type c lls 
with epithelioid changes consistent with their acti- 
vation. Further studies are ongoing to demonstrate 
whether these cells produce mediators uch as cyto- 
kines and tissue factor, which could certainly contrib- 
ute to the initiation and propagation of procoagulant 
events, culminating in the generation of thrombin. 
In conclusion, patients with the Thermo Cardio- 
systems HeartMate 1000 IP LVAD have evidence of 
enhanced thrombin generation with fibrinolysis. 
Thus, despite the apparent clinical stability of pa- 
tients having an LVAD, as well as a low incidence of 
clinically apparent or subclinical microemboli, our 
results identify the presence of a coagulopathy with 
the potential to exacerbate bleeding or clotting 
complications in clinically relevant settings, for ex- 
ample, operation, infection, or inflammatory stress. 
The current balance appears to result in a favorably 
low thromboembolic rate; however, studies to deter- 
mine the mechanisms triggering perturbation of the 
procoagulant and fibrinolytic pathways in patients 
having an LVAD are essential to identify targets of 
potential therapeutic intervention in these patients 
if necessitated by the development of hemostatic 
complications associated with long-term use of this 
device. 
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